Combining FAK and RAF/MEK inhibitors has shown clinical activity in low-grade serous ovarian cancer regardless of KRAS mutation status [62] with an ongoing registration-directed study of VS-6766 (RAF/MEK inhibitor) ± defactinib (FAK inhibitor) in patients with recurrent low-grade serous ovarian cancer (ENGOT-ov60/NCRI/GOG-3052; NCT04625270) underway [51]. This evidence concerns the gene PTK2 and ovarian serous adenocarcinoma.